Nantkwest Inc (NASDAQ:NK) Short Interest Update
Nantkwest Inc (NASDAQ:NK) was the target of a significant drop in short interest during the month of November. As of November 29th, there was short interest totalling 2,380,000 shares, a drop of 16.2% from the November 14th total of 2,840,000 shares. Based on an average trading volume of 179,500 shares, the short-interest ratio is currently 13.3 days. Approximately 8.6% of the company’s shares are short sold.
Separately, ValuEngine cut shares of Nantkwest from a “buy” rating to a “hold” rating in a report on Wednesday.
Shares of NK stock traded up $0.28 during trading on Thursday, reaching $2.20. The company’s stock had a trading volume of 885,784 shares, compared to its average volume of 322,148. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.72 and a quick ratio of 5.72. The company has a market capitalization of $216.41 million, a price-to-earnings ratio of -1.80 and a beta of 2.54. The stock’s 50-day moving average price is $1.29 and its 200 day moving average price is $1.22. Nantkwest has a 1-year low of $0.93 and a 1-year high of $2.30.
Several hedge funds have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC purchased a new position in Nantkwest in the second quarter worth approximately $37,000. Tower Research Capital LLC TRC lifted its stake in Nantkwest by 4,218.8% in the third quarter. Tower Research Capital LLC TRC now owns 47,766 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 46,660 shares during the last quarter. Morgan Stanley lifted its stake in Nantkwest by 303.8% in the second quarter. Morgan Stanley now owns 48,497 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 36,486 shares during the last quarter. Jane Street Group LLC purchased a new position in Nantkwest in the second quarter worth approximately $92,000. Finally, Paloma Partners Management Co purchased a new position in Nantkwest in the second quarter worth approximately $127,000. Hedge funds and other institutional investors own 5.47% of the company’s stock.
Nantkwest Company Profile
NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.